MedKoo Cat#: 527064 | Name: Bupropion free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bupropion, also known as amfebutamone and BW 323, is a norepinephrine–dopamine reuptake inhibitor (NDRI) and a nicotinic receptor antagonist. However, its effects on dopamine are weak and clinical significance is contentious. Chemically, bupropion is an aminoketone that belongs to the class of substituted cathinones and more generally that of substituted amphetamines and substituted phenethylamines.

Chemical Structure

Bupropion free base
Bupropion free base
CAS#34911-55-2 (free base)

Theoretical Analysis

MedKoo Cat#: 527064

Name: Bupropion free base

CAS#: 34911-55-2 (free base)

Chemical Formula: C13H18ClNO

Exact Mass: 239.1077

Molecular Weight: 239.74

Elemental Analysis: C, 65.13; H, 7.57; Cl, 14.79; N, 5.84; O, 6.67

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Bupropion free base; amfebutamone; Bupropion, Wellbutrin, Zyban; BW 323; BW-323; BW323. NSC 315851; NSC-315851; NSC315851;
IUPAC/Chemical Name
2-(tert-Butylamino)-1-(3-chlorophenyl)propan-1-one
InChi Key
SNPPWIUOZRMYNY-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
SMILES Code
CC(NC(C)(C)C)C(C1=CC=CC(Cl)=C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 239.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Bupropion. 2024 Jan 15. PMID: 30000243. 2: Bakouni H, Sharafi H, Bahremand A, Drouin S, Ziegler D, Bach P, Le Foll B, Schütz CG, Tardelli V, Ezard N, Siefried K, Jutras-Aswad D. Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials. Drug Alcohol Depend. 2023 Dec 1;253:111018. doi: 10.1016/j.drugalcdep.2023.111018. Epub 2023 Nov 4. PMID: 37979478. 3: Jiang Q, Velu P, Sohouli MH, Ziamanesh F, Shojaie S, Fatahi S, Li Q. The effects of bupropion alone and combined with naltrexone on blood pressure and CRP concentration: A systematic review and meta-regression analysis of randomized controlled trials. Eur J Clin Invest. 2024 Mar;54(3):e14118. doi: 10.1111/eci.14118. Epub 2023 Nov 4. PMID: 37924302. 4: McCarthy B, Bunn H, Santalucia M, Wilmouth C, Muzyk A, Smith CM. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder. Clin Psychopharmacol Neurosci. 2023 Nov 30;21(4):609-616. doi: 10.9758/cpn.23.1081. Epub 2023 Jul 17. PMID: 37859435; PMCID: PMC10591164. 5: Patel AR, Panchal JR, Desai CK. Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials. Indian J Psychiatry. 2023 May;65(5):526-533. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_218_22. Epub 2023 May 15. PMID: 37397838; PMCID: PMC10309263. 6: Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. Bupropion. 2023 Jul. PMID: 35951874. 7: Aikoye S, Basiru TO, Nwoye I, Adereti I, Asuquo S, Ezeokoli A, Hardy J, Umudi O. A Systematic Review of Abuse or Overprescription of Bupropion in American Prisons and a Synthesis of Case Reports on Bupropion Abuse in American Prison and Non-prison Systems. Cureus. 2023 Mar 15;15(3):e36189. doi: 10.7759/cureus.36189. PMID: 37065297; PMCID: PMC10104426. 8: Keam SJ. Dextromethorphan/Bupropion: First Approval. CNS Drugs. 2022 Nov;36(11):1229-1238. doi: 10.1007/s40263-022-00968-4. PMID: 36301443. 9: Oravecz R, Stuhec M. Bupropion XL unapproved use in the prisons: Two cases focused on the bupropion pharmacology. Psychiatr Hung. 2022;37(3):246-249. PMID: 36264167. 10: Dahlberg S, Chang ET, Weiss SR, Dopart P, Gould E, Ritchey ME. Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review. Diabetes Metab Syndr Obes. 2022 Sep 29;15:3049-3067. doi: 10.2147/DMSO.S381652. PMID: 36200062; PMCID: PMC9529009. 11: Correa-Morales JE, Cuellar-Valencia L, Mantilla-Manosalva N, Quintero-Muñoz E, Iriarte-Aristizábal MF, Giraldo-Moreno S, Rodríguez-Campos LF. Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. J Pain Symptom Manage. 2023 Jan;65(1):e21-e28. doi: 10.1016/j.jpainsymman.2022.09.011. Epub 2022 Oct 2. PMID: 36198335. 12: El Hayek SA, Shatila MA, Adnan JA, Geagea LE, Kobeissy F, Talih FR. Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia? Expert Rev Neurother. 2022 Sep;22(9):737-749. doi: 10.1080/14737175.2022.2124369. Epub 2022 Sep 14. PMID: 36093756. 13: Vismara M, Benatti B, Nicolini G, Cova I, Monfrini E, Di Fonzo A, Fetoni V, Viganò CA, Priori A, Dell'Osso B. Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review. BMC Neurol. 2022 May 5;22(1):169. doi: 10.1186/s12883-022-02668-4. PMID: 35513785; PMCID: PMC9069850. 14: Guo K, Wang S, Shang X, E F, Hou L, Li J, Li Y, Yang K, Li X. The effect of Varenicline and Bupropion on smoking cessation: A network meta-analysis of 20 randomized controlled trials. Addict Behav. 2022 Aug;131:107329. doi: 10.1016/j.addbeh.2022.107329. Epub 2022 Apr 5. PMID: 35397262. 15: Rianprakaisang TN, Prather CT, Lin AL, Murray BP, Hendrickson RG; Toxicology Investigators Consortium (ToxIC). Factors associated with seizure development after bupropion overdose: a review of the toxicology investigators consortium. Clin Toxicol (Phila). 2021 Dec;59(12):1234-1238. doi: 10.1080/15563650.2021.1913180. Epub 2021 Apr 21. PMID: 33878992. 16: Sposito AC, Bonilha I, Luchiari B, Benchimol A, Hohl A, Moura F, Cercato C, Geloneze B, Nadruz W, Aguilar-Salinas C, Carvalho LSF. Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. Obes Rev. 2021 Jun;22(6):e13224. doi: 10.1111/obr.13224. Epub 2021 Apr 12. PMID: 33847068. 17: MacDonald E, Horton J. Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dysthymia) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. PMID: 34260168. 18: Tran K, McGill SC, Horton J. Bupropion for Treatment-Resistant Depression [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. PMID: 34260167. 19: Lee WK, Au Yeung KL, Lam HB, Wong CK, Wong TC, Fu CK, Sham SK, Au MK, Lam TC, Ki-Yan Mak D. Consensus statements on the clinical understanding and use of bupropion in Hong Kong. CNS Neurosci Ther. 2021 Mar;27 Suppl 1(Suppl 1):20-24. doi: 10.1111/cns.13376. PMID: 33555615; PMCID: PMC7869927. 20: González-Urbieta I, Jafferany M, Torales J. Bupropion in dermatology: A brief update. Dermatol Ther. 2021 Jan;34(1):e14303. doi: 10.1111/dth.14303. Epub 2020 Sep 22. PMID: 32926554.